Baroda Bnp Paribas Health and Wellness Fund
Baroda BNP Paribas Mutual Fund · FM: Rohan Korde, Ankeet Pandya · INF251K01VA5 · Direct
NAV ₹11.08 AUM ₹553 Cr as of 22 Sep 2026
Latest available portfolio · Retrieved: 8-Aug-2026 11:29 PM IST · Disclosure date not provided
Returns
| 1D | 1M | 3M | 6M | 1Y | 3Y | 5Y | Rank (1Y) | TER | |
|---|---|---|---|---|---|---|---|---|---|
| Fund | -0.5% | +1.0% | +7.0% | +19.7% | +12.6% | — | — | 48/234 | 1.51% |
Equity allocation
98.03%
Non-equity allocation (combined)
1.97%
All Equity Holdings (31) latest available
| # | Company | Value (₹ Cr) | % of AUM | Change |
|---|---|---|---|---|
| 1 | Sun Pharmaceuticals Industries Ltd | 41.9 | 7.58% | — |
| 2 | Lupin Ltd | 36.3 | 6.56% | — |
| 3 | Laurus Labs Ltd | 34.9 | 6.31% | — |
| 4 | Ipca Laboratories Ltd | 32.1 | 5.80% | — |
| 5 | Torrent Pharmaceuticals Ltd | 30.0 | 5.43% | — |
| 6 | Divi's Laboratories Ltd | 29.6 | 5.35% | — |
| 7 | Apollo Hospitals Enterprise Ltd | 26.9 | 4.87% | — |
| 8 | J.B. Chemicals & Pharmaceuticals Ltd | 25.2 | 4.57% | — |
| 9 | Fortis Healthcare Ltd | 23.9 | 4.32% | — |
| 10 | AstraZeneca Pharma India Ltd | 21.4 | 3.87% | — |
| 11 | Emcure Pharmaceuticals Ltd | 19.9 | 3.60% | — |
| 12 | SBI Life Insurance Co Ltd | 17.7 | 3.19% | — |
| 13 | Glenmark Pharmaceuticals Ltd | 17.6 | 3.19% | — |
| 14 | Mankind Pharma Ltd | 16.6 | 2.99% | — |
| 15 | Aurobindo Pharma Ltd | 15.8 | 2.85% | — |
| 16 | Dr. Lal PathLabs Ltd | 14.0 | 2.53% | — |
| 17 | Zydus Lifesciences Ltd | 13.9 | 2.51% | — |
| 18 | Aster DM Quality Care Ltd Ordinary Shares | 13.3 | 2.41% | — |
| 19 | Acutaas Chemicals Ltd | 12.7 | 2.30% | — |
| 20 | Max Financial Services Ltd | 12.4 | 2.25% | — |
| 21 | Abbott India Ltd | 11.4 | 2.07% | — |
| 22 | Ajanta Pharma Ltd | 10.8 | 1.95% | — |
| 23 | Nephrocare Health Services Ltd | 10.2 | 1.84% | — |
| 24 | Concord Biotech Ltd | 9.6 | 1.74% | — |
| 25 | Inventurus Knowledge Solutions Ltd | 8.4 | 1.52% | — |
| 26 | Metropolis Healthcare Ltd | 7.0 | 1.27% | — |
| 27 | Dr Reddy's Laboratories Ltd | 6.8 | 1.23% | — |
| 28 | Medplus Health Services Ltd | 6.5 | 1.17% | — |
| 29 | Gland Pharma Ltd | 6.2 | 1.13% | — |
| 30 | Cipla Ltd | 5.9 | 1.06% | — |
| 31 | Procter & Gamble Health Ltd | 3.2 | 0.57% | — |
All disclosed equity positions are shown. Non-equity allocation is the remaining portfolio weight after disclosed equities.